Analysis of Biomarker Approaches & Clinical Endpoints for Neovascular Retinal Disorders
Time: 1:01 pm
day: Pre-Conference Day
Details:
This workshop will focus on the critical role of biomarkers and clinical endpoints in the development of therapies for neovascular retinal disorders, including diabetic retinopathy (DR) and wet age-related macular degeneration (AMD). Participants will engage in discussions surrounding the complexities of endpoint selection, the advancements in imaging technologies, and the implications of emerging biomarkers for drug development.
- Explore the limitations of traditional anatomical endpoints in clinical trials for diabetic retinopathy (DR) and wet AMD, discussing the current landscape of surrogate biomarkers to expedite results
- Identify emerging biomarkers in neovascular retinal disorders and their potential roles in clinical development
- Discuss the challenges of selecting and validating biomarkers, particularly regarding imaging technologies like OCTA and microperimetry
- Evaluate the causal relationships between biomarkers and disease progression to optimize drug development and validate surrogate biomarkers
- Highlight the impact of technological advancements on biomarker identification and the role of AI in data analysis
- Emphasize the importance of reliable imaging devices and methodologies for consistent biomarker assessment and endpoint validation
